Integral Health Asset Management’s Regenxbio RGNX Stock Holding History

Integral Health Asset Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.6M	Buy	1,500,000 +300,000	+25%	+$3.15M	0.6%	45
2025 Q4	$17.3M	Buy	1,200,000 +100,000	+9%	+$1.25M	0.86%	41
2025 Q3	$10.6M	Buy	1,100,000 +400,000	+57%	+$3.54M	0.72%	50
2025 Q2	$5.75M	Sell	700,000 -225,000	-24%	-$1.88M	0.53%	48
2025 Q1	$6.61M	Buy	925,000 +25,000	+3%	+$186K	0.7%	43
2024 Q4	$6.96M	Sell	900,000 -375,000	-29%	-$3.52M	0.59%	54
2024 Q3	$13.4M	Buy	1,275,000 +325,000	+34%	+$3.96M	1.5%	19
2024 Q2	$11.1M	Buy	950,000 +190,000	+25%	+$2.96M	1.06%	32
2024 Q1	$16M	Buy	760,000 +435,000	+134%	+$7.74M	1.49%	24
2023 Q4	$5.83M	Buy	+325,000	New	+$5.72M	0.79%	53
2022 Q2	–	Sell	-90,000	Closed	-$2.99M	–	82
2022 Q1	$2.99M	Buy	90,000 +15,000	+20%	+$417K	0.78%	46
2021 Q4	$2.45M	Buy	75,000 +20,000	+36%	+$681K	0.68%	46
2021 Q3	$2.31M	Buy	+55,000	New	+$1.98M	0.66%	52

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Integral Health Asset Management's RGNX Position: Q1 2026 in Review

Integral Health Asset Management increased its Regenxbio (RGNX) stake by 25% in Q1 2026, buying an estimated $3.15M and bringing the position to 1,500,000 shares worth $12.6M. The position accounts for 0.6% of the portfolio, ranked #45.

Integral Health Asset Management first reported a position in RGNX in Q3 2021 and has held it in 13 quarters since. The position peaked at $17.3M in Q4 2025. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

Integral Health Asset Management held 1,500,000 shares of Regenxbio worth $12.6M as of Q1 2026.
Integral Health Asset Management bought 300,000 Regenxbio shares in Q1 2026, an estimated $3.15M.
Regenxbio made up 0.6% of Integral Health Asset Management's portfolio in Q1 2026, its #45 holding.
Integral Health Asset Management first reported a position in Regenxbio in Q3 2021 and has held it in 13 quarters since.
Integral Health Asset Management's Regenxbio position peaked at $17.3M in Q4 2025.
178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.